-
Product Insights
New![]()
Net Present Value Model: Dynavax Technologies Corp’s Z-1018
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Profile
![]()
Dynavax Technologies Corp – Company Profile
Dynavax Technologies Corp (Dynavax) is an biopharmaceutical company that develops novel vaccines based on Toll-like receptor(TLR) biology and also focuses on Various infectious and inflammatory diseases. The company marketed product Heplisav-B is an adult vaccine which is indicated for the prevention of hepatitis B. The company’s pipeline focuses on combining the innate immune response with other immunomodulatory agents for the treatment of cancer. Its ongoing studies include DV2-ZOS-01 for immune-mediated, herpes zoster, and anaphylaxis events, DV2-HBV-27 for the pregnancy registry....
Add to Basket -
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BCMA-CAR-T in Multiple Myeloma (Kahler Disease)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.BCMA-CAR-T in Multiple Myeloma (Kahler Disease) Drug Details:Gene-modified cell therapy is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Z-1018 in Herpes Zoster (Shingles)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Z-1018 in Herpes Zoster (Shingles) Drug Details:Z-1018 is under development for the prevention of herpes zoster...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Sales Analysis and Forecast, H2 2022
COVID-19 Analyst Consensus Sales Report Overview Prophylactic COVID-19 vaccines are projected to generate total sales of $264 billion from 2021 to 2028. The number of COVID-19 drugs with forecast sales nearly tripled due to the massive mandatory vaccination campaigns led by the major markets, which caused rapid increases in COVID-19 vaccines. BioNTech/Pfizer’s Comirnaty, Moderna’s Spikevax, and Pfizer’s Paxlovid are the top three marketed drugs with the highest peak forecast sales. Comparing Q4 2020 and H2 2022 total COVID-19 forecast sales within...
-
Product Insights
![]()
Net Present Value Model: CpG 1018
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model CpG 1018 Drug Details Vaccine candidate...
-
Product Insights
![]()
Net Present Value Model: Heplisav-B
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Heplisav-B Drug Details Hepatitis B vaccine...
-
Track & Monitor
![]()
Immuno-oncology in Pharmaceuticals: Gene therapy for cancers
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – Z-1018
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Z-1018 Drug Details Z-1018 is under development for the prevention of herpes zoster (shingles)...
-
Product Insights
Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Shingles (herpes zoster) is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and a weakened immune system. The Herpes Zoster (Shingles) pipeline drugs market research report provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Anthrax Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Anthrax pipeline market research report provides comprehensive information on the therapeutics under development for Anthrax, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anthrax and features dormant and discontinued projects.
-
Product Insights
Toll Like Receptor 8 (CD288 or TLR8) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Toll-like receptor 8 is a protein encoded by the TLR8 gene. It acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. The Toll Like Receptor 8 (CD288 or TLR8) Development market research report provides an in-depth analysis of Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information on the Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of...
-
Product Insights
Rheumatoid Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to the destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue and fever, and weight loss. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications, and immunosuppressants. The Rheumatoid Arthritis Drugs in Development market research report provides an overview of the Rheumatoid Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis, complete with analysis by stage...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Analyst Consensus Drug Sales Forecast – Q3, 2020
This report contains a summary of the analyst consensus forecasts available in the GlobalData Pharma Intelligence Center Drug Sales and Analyst Consensus Database for the Indication COVID-19. Currently there are 23 drugs indicated for COVID-19 which have analyst consensus forecasts available.
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Pipeline of Small and Mid-Cap Bio/Pharma Companies
The coronavirus (COVID-19) company impact report analyses how the pandemic has impact Small and Mid Bio/Pharma Companies.
-
Sector Analysis
EU5 Prefabricated Crown and Bridge Materials Outlook to 2025
“What is covered in the report about the “EU5 Prefabricated Crown and Bridge Materials Market”? GlobalData’s “EU5 Prefabricated Crown and Bridge Materials Market Outlook to 2025” report is a comprehensive databook report, covering key market data on the EU5 Prefabricated Crown and Bridge Materials market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Permanent Crowns and Permanent Bridges. The EU5 Prefabricated Crown and Bridge Materials Market report provides key information and data...
-
Product Insights
Hepatitis B Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Hepatitis B Global Clinical Trials Review, H2, 2016" provides an overview of Hepatitis B clinical trials scenario. This report provides top line data relating to the clinical trials on Hepatitis B. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) Global Clinical Trials Review, H1, 2019" provides an overview of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) clinical trials scenario. This report provides top line data relating to the clinical trials on End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by...
-
Product Insights
Ragweed Pollen Allergy Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Ragweed Pollen Allergy Global Clinical Trials Review, H1, 2018" provides an overview of Ragweed Pollen Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Ragweed Pollen Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.